SCYNEXIS (SCYX)
Market Price (6/19/2026): $4.05 | Market Cap: $25.8 MilSector: Health Care | Industry: Pharmaceuticals
SCYNEXIS (SCYX)
Market Price (6/19/2026): $4.05Market Cap: $25.8 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -222% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 674% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Anti-infective Drug Development, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -114%, 3Y Excs Rtn is -154% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -120% Weak revenue growthRev Chg QQuarterly Revenue Change % is null Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% Key risksSCYX key risks include [1] a high cash burn rate requiring potentially dilutive financing, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -222% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 674% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Anti-infective Drug Development, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -114%, 3Y Excs Rtn is -154% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -120% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% |
| Key risksSCYX key risks include [1] a high cash burn rate requiring potentially dilutive financing, Show more. |
Qualitative Assessment
AI Analysis | Feedback
SCYNEXIS (SCYX) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Significant Miss in Fiscal Q1 2026 Earnings. SCYNEXIS reported its fiscal Q1 2026 earnings on May 10, 2026, posting an earnings per share (EPS) of -$3.36. This figure substantially missed analysts' consensus expectations of -$0.96, representing a 250.00% miss. The company's stock declined by 5.34% on May 11, 2026, following the earnings release. This miss was partly attributed to a 140% increase in research and development expenses, reaching $12.4 million, primarily driven by an $8.0 million in-process research and development (IPR&D) expense recognized for the acquisition of SCY-770.
2. Implementation of a 1-for-8 Reverse Stock Split. On May 22, 2026, SCYNEXIS announced a 1-for-8 reverse stock split of its common stock, effective May 29, 2026, with split-adjusted trading commencing on June 1, 2026. The primary rationale for this action was to regain compliance with Nasdaq's minimum bid price requirement for continued listing. This corporate action reduced the number of outstanding common shares from approximately 79.5 million to around 9.9 million. Reverse stock splits are often perceived negatively by investors, as they can signal a company's struggle to maintain its stock value and may lead to reduced liquidity and ongoing investor apprehension.
Show more
SCYNEXIS (SCYX) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Significant Miss in Fiscal Q1 2026 Earnings. SCYNEXIS reported its fiscal Q1 2026 earnings on May 10, 2026, posting an earnings per share (EPS) of -$3.36. This figure substantially missed analysts' consensus expectations of -$0.96, representing a 250.00% miss. The company's stock declined by 5.34% on May 11, 2026, following the earnings release. This miss was partly attributed to a 140% increase in research and development expenses, reaching $12.4 million, primarily driven by an $8.0 million in-process research and development (IPR&D) expense recognized for the acquisition of SCY-770.
2. Implementation of a 1-for-8 Reverse Stock Split. On May 22, 2026, SCYNEXIS announced a 1-for-8 reverse stock split of its common stock, effective May 29, 2026, with split-adjusted trading commencing on June 1, 2026. The primary rationale for this action was to regain compliance with Nasdaq's minimum bid price requirement for continued listing. This corporate action reduced the number of outstanding common shares from approximately 79.5 million to around 9.9 million. Reverse stock splits are often perceived negatively by investors, as they can signal a company's struggle to maintain its stock value and may lead to reduced liquidity and ongoing investor apprehension.
3. Dilutive Private Placement. SCYNEXIS completed a private placement on April 1, 2026, following an announcement on March 31, 2026, which generated net proceeds of approximately $37.2 million. While this financing extended the company's cash runway to mid-2029, it involved the issuance of common stock and associated common warrants, with the potential to raise an additional $52.2 million if fully exercised. The issuance of new equity and warrants can create a dilutive effect on existing shareholders, contributing to downward pressure on the stock price.
Show less
Stock Movement Drivers
Fundamental Drivers
The -32.5% change in SCYX stock from 2/28/2026 to 6/18/2026 was primarily driven by a -90.1% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6182026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.00 | 4.05 | -32.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 20 | 593.9% |
| P/S Multiple | 12.8 | 1.3 | -90.1% |
| Shares Outstanding (Mil) | 6 | 6 | -2.1% |
| Cumulative Contribution | -32.5% |
Market Drivers
2/28/2026 to 6/18/2026| Return | Correlation | |
|---|---|---|
| SCYX | -32.5% | |
| Market (SPY) | 9.2% | 38.9% |
| Sector (XLV) | -6.4% | 28.3% |
Fundamental Drivers
The -26.6% change in SCYX stock from 11/30/2025 to 6/18/2026 was primarily driven by a -89.2% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6182026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.52 | 4.05 | -26.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 20 | 593.9% |
| P/S Multiple | 11.7 | 1.3 | -89.2% |
| Shares Outstanding (Mil) | 6 | 6 | -2.1% |
| Cumulative Contribution | -26.6% |
Market Drivers
11/30/2025 to 6/18/2026| Return | Correlation | |
|---|---|---|
| SCYX | -26.6% | |
| Market (SPY) | 9.9% | 31.7% |
| Sector (XLV) | -4.4% | 21.5% |
Fundamental Drivers
The -42.1% change in SCYX stock from 5/31/2025 to 6/18/2026 was primarily driven by a -92.3% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6182026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.00 | 4.05 | -42.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 20 | 673.5% |
| P/S Multiple | 16.4 | 1.3 | -92.3% |
| Shares Outstanding (Mil) | 6 | 6 | -3.0% |
| Cumulative Contribution | -42.1% |
Market Drivers
5/31/2025 to 6/18/2026| Return | Correlation | |
|---|---|---|
| SCYX | -42.1% | |
| Market (SPY) | 28.1% | 19.3% |
| Sector (XLV) | 14.6% | 9.4% |
Fundamental Drivers
The -79.7% change in SCYX stock from 5/31/2023 to 6/18/2026 was primarily driven by a -94.1% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6182026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.00 | 4.05 | -79.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 20 | 267.6% |
| P/S Multiple | 21.6 | 1.3 | -94.1% |
| Shares Outstanding (Mil) | 6 | 6 | -6.3% |
| Cumulative Contribution | -79.8% |
Market Drivers
5/31/2023 to 6/18/2026| Return | Correlation | |
|---|---|---|
| SCYX | -79.8% | |
| Market (SPY) | 85.7% | 21.2% |
| Sector (XLV) | 22.9% | 17.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SCYX Return | -20% | -74% | 43% | -46% | -48% | -25% | -94% |
| Peers Return | 2% | -9% | -30% | 38% | -1% | 2% | -10% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| SCYX Win Rate | 33% | 25% | 50% | 42% | 33% | 67% | |
| Peers Win Rate | 48% | 45% | 32% | 45% | 48% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SCYX Max Drawdown | -50% | -78% | -57% | -64% | -60% | -57% | |
| Peers Max Drawdown | -39% | -36% | -44% | -40% | -43% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MTNB, GILD, MRK, PFE, PULM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | SCYX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.2% | -18.8% |
| % Gain to Breakeven | 52.1% | 23.1% |
| Time to Breakeven | 107 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -26.5% | -6.7% |
| % Gain to Breakeven | 36.1% | 7.1% |
| Time to Breakeven | 5 days | 31 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -69.1% | -19.2% |
| % Gain to Breakeven | 223.5% | 23.8% |
| Time to Breakeven | 52 days | 105 days |
In The Past
SCYNEXIS's stock fell -34.2% during the 2025 US Tariff Shock. Such a loss loss requires a 52.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SCYX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.2% | -18.8% |
| % Gain to Breakeven | 52.1% | 23.1% |
| Time to Breakeven | 107 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -26.5% | -6.7% |
| % Gain to Breakeven | 36.1% | 7.1% |
| Time to Breakeven | 5 days | 31 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -69.1% | -19.2% |
| % Gain to Breakeven | 223.5% | 23.8% |
| Time to Breakeven | 52 days | 105 days |
In The Past
SCYNEXIS's stock fell -34.2% during the 2025 US Tariff Shock. Such a loss loss requires a 52.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About SCYNEXIS (SCYX)
SCYNEXIS, Inc. is a biotechnology company dedicated to developing and commercializing innovative treatments for fungal infections. Its primary commercially available product is BREXAFEMME (ibrexafungerp tablets), which is approved for the treatment of vulvovaginal candidiasis (VVC) in the United States.
The company's lead compound, ibrexafungerp, is also in advanced development for a wider range of fungal infections. This includes its use for the prevention of recurrent VVC, where it has completed a Phase 3 study, and as a novel oral and intravenous therapy for severe conditions such as invasive aspergillosis, invasive candidiasis, and various refractory invasive fungal infections. To expand the development and commercialization reach of ibrexafungerp, SCYNEXIS has established research collaborations with pharmaceutical partners like Merck, Hansoh, and R-Pharm, primarily targeting the pharmaceutical market by serving patients in need of improved antifungal therapies.
AI Analysis | Feedback
Here are 1-2 brief analogies for SCYNEXIS (SCYX):
Think of it as a "Vertex Pharmaceuticals for fungal infections," focusing intensely on a specific disease area with a key drug pipeline.
A smaller, specialized biotech akin to a "mini-Gilead Sciences," but exclusively dedicated to developing anti-fungal treatments.
AI Analysis | Feedback
- BREXAFEMME (ibrexafungerp tablets): An approved oral drug for the treatment of vulvovaginal candidiasis (VVC).
- Ibrexafungerp (pipeline): A novel oral and intravenous antifungal drug candidate in development for various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections, as well as for the prevention of recurrent VVC.
AI Analysis | Feedback
SCYNEXIS (SCYX), a biotechnology company, engages in research collaborations to develop and commercialize rights for its lead product candidate, ibrexafungerp. These collaborations represent significant business relationships from which SCYNEXIS derives value, making these companies its major customers for these rights.
The major customer companies identified from the provided description are:
- Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc. - MRK)
- Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Limited (3692.HK)
- R-Pharm, CJSC (private company)
AI Analysis | Feedback
- Siegfried AG (SWX: SFZN)
- Thermo Fisher Scientific, Inc. (NYSE: TMO)
AI Analysis | Feedback
David Angulo, M.D. President and Chief Executive Officer
Dr. Angulo became President and Chief Executive Officer of SCYNEXIS in January 2023, having previously served as Chief Medical Officer since 2015. An infectious disease specialist, he brings over 20 years of experience in drug development. Prior to joining SCYNEXIS, he was Vice President, Research and Development at Brickell Biotech, Inc. Dr. Angulo also held various senior positions at Stiefel Laboratories, Inc., a GSK company, where he led the clinical and medical departments. Additionally, he was responsible for several anti-infective development programs at Schering-Plough Research Institute.
Ivor Macleod, MBA, CPA Chief Financial Officer
Mr. Macleod joined SCYNEXIS as Chief Financial Officer on October 24, 2022. He is a senior pharmaceutical executive with over 30 years of financial and operational experience in the life sciences industry. Before SCYNEXIS, Mr. Macleod served as Chief Financial Officer of Athersys, Inc. from January 2020. His prior roles include Chief Financial Officer and Chief Compliance Officer of Eisai Inc. from 2015 to 2018, and Vice President Finance – Merck Research Labs at Merck & Co., Inc. from 2012 to 2015. He also held positions at F. Hoffmann-La Roche Ltd. from 1998 to 2012.
Scott Sukenick Chief Legal Officer & Corporate Secretary
Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017, bringing over a decade of experience addressing legal challenges for innovative life sciences companies. He previously worked at Cooley LLP, specializing in life sciences litigation and strategic intellectual property management, and at Patterson Belknap Webb & Tyler LLP, where he focused on patent litigation for pharmaceutical and medical device companies. He began his career at Simpson Thacher & Bartlett LLP, concentrating on complex commercial litigation and intellectual property transactional matters.
Daniella Gigante Vice President, Human Resources and Information Technology
Ms. Gigante joined SCYNEXIS in October 2020 to lead the Human Resources and IT functions. She possesses over 22 years of Human Resources experience across various industries, including consulting, banking, pharmaceutical, and biotechnology. Before SCYNEXIS, she spent eight years at Allergan as Executive Director of Talent Acquisition and held leadership roles in Talent Acquisition at Pfizer and Schering-Plough.
Rossana Ferrara-Pontoriero, Ph.D. Vice President, Business Development and Alliance Management
Dr. Ferrara-Pontoriero joined SCYNEXIS in September 2016 and has held various leadership roles in Commercial, Business Development, Strategic Planning, and Alliance Management. She is a Commercial and Business Development executive with over 11 years of experience in the Pharmaceutical and Biotechnology industries, with previous marketing roles at Celgene and Allergan, and global commercial assessments at Forest Laboratories.
AI Analysis | Feedback
The key risks to SCYNEXIS (SCYX) predominantly revolve around the successful development and commercialization of its drug pipeline and its financial stability.
- Dependence on SCY-247 Development and Regulatory Approval: SCYNEXIS has licensed its first product, BREXAFEMME, to GSK and is now primarily focused on advancing its second-generation antifungal compound, SCY-247. The success of SCYNEXIS's business largely hinges on the outcomes of SCY-247's ongoing clinical trials (such as the Phase 1 study for the intravenous formulation, with topline data expected in the second half of 2026, and a planned Phase 2 study for invasive candidiasis in 2026) and its ability to secure subsequent regulatory approvals for these indications. Delays or failures in clinical development or difficulties in obtaining regulatory approvals for SCY-247 could significantly impact the company's future commercial prospects and valuation.
- Commercialization Challenges and Market Acceptance for BREXAFEMME (under GSK): Although SCYNEXIS licensed BREXAFEMME to GSK, the company is still eligible for significant development, regulatory, commercial, and sales milestones, as well as royalties, based on its performance. BREXAFEMME faced a voluntary recall in 2023 due to potential manufacturing cross-contamination, leading to its unavailability in the market. While the New Drug Application (NDA) transfer to GSK was completed by the end of 2025, there is no confirmed timeline for the drug's return to pharmacies. Even prior to the recall, BREXAFEMME encountered considerable pricing and reimbursement hurdles compared to generic alternatives, which affected its initial sales. The inability of GSK to successfully re-launch and effectively commercialize BREXAFEMME, or achieve substantial market penetration due to pricing, competition, or lingering perceptions from the recall, poses a significant risk to SCYNEXIS's anticipated revenue streams.
- Financial Stability and Nasdaq Listing Compliance: SCYNEXIS has a limited history of profitability. While a one-time payment of $24.8 million from GSK in Q4 2025 helped extend its cash runway to more than two years (as of March 2026), the company has historically relied on external funding to support its operations and development activities. Furthermore, in June 2025, SCYNEXIS received a Nasdaq bid-price deficiency notice because its shares traded below $1.00 for 30 consecutive sessions, indicating a risk of delisting if it fails to regain compliance. Delisting could negatively impact the company's stock price and its ability to access capital markets, which is crucial for funding ongoing research and development.
AI Analysis | Feedback
AI Analysis | Feedback
SCYNEXIS (symbol: SCYX) operates in several addressable markets related to fungal infections:
- Vulvovaginal Candidiasis (VVC): The global vulvovaginal candidiasis treatment market was valued at approximately USD 1 billion in 2023 and is projected to reach USD 1.5 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.5% between 2024 and 2032. Another estimate places the global market at USD 1.0 billion in 2023, projected to reach USD 1.6 billion by 2033, with a CAGR of 4.4%. North America held the largest share of the global market. The U.S. VVC market is substantial, with millions of cases diagnosed annually.
- Recurrent Vulvovaginal Candidiasis (RVVC): While a distinct market size is not consistently reported separately from the broader VVC market, BREXAFEMME is approved to reduce the incidence of recurrent vulvovaginal candidiasis. Globally, recurrent VVC affects more than 9% of women annually.
- Invasive Aspergillosis: The global aspergillosis treatment market size was valued at USD 4.4 billion in 2024 and is poised to grow to USD 6.65 billion by 2033, exhibiting a CAGR of 4.7% during the forecast period (2026-2033). In the U.S. specifically, the aspergillosis market was nearly USD 1,125 million in 2023 and is anticipated to increase at an approximate CAGR of 10%.
- Invasive Candidiasis: The market for invasive candidiasis across the 7 major markets (United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan) reached USD 2.7 billion in 2024 and is expected to reach USD 3.3 billion by 2035, with a CAGR of 3.34% during 2025-2035. Approximately 75,000 cases of invasive candidiasis occur annually in the United States.
- Refractory Invasive Fungal Infections: null
AI Analysis | Feedback
SCYNEXIS, Inc. (SCYX) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives related to its antifungal product portfolio and strategic partnerships.
- Relaunch of BREXAFEMME by GSK and Associated Milestones/Royalties: Following the successful transfer of the BREXAFEMME New Drug Application (NDA) to GlaxoSmithKline (GSK) in November 2025, GSK is preparing for its relaunch. SCYNEXIS is positioned to receive up to $145.5 million in annual net sales milestones, in addition to low to mid-single-digit royalties from net sales of BREXAFEMME for vulvovaginal candidiasis (VVC).
- Milestone Payments from GSK for Ibrexafungerp in Invasive Fungal Infections: The global license agreement with GSK, initially announced in March 2023, includes potential milestone payments for the development and commercialization of ibrexafungerp for severe, hospital-setting indications, such as invasive candidiasis (IC). Successful advancement of ibrexafungerp for these indications could trigger up to $245.5 million in additional payments from GSK. GSK has expressed commitment to maximizing the overall potential of ibrexafungerp.
- Advancement of SCY-247 Through Clinical Development: SCYNEXIS's second-generation antifungal drug, SCY-247, is progressing through Phase 1 clinical trials for both oral and intravenous (IV) formulations. Topline data for the IV formulation is expected in the second half of 2026, with a Phase 2 proof-of-concept study in invasive candidiasis planned for later in 2026. SCY-247 has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, which are intended to accelerate its development. The company also plans to initiate an expanded access program for SCY-247 in the first half of 2026.
AI Analysis | Feedback
Share Issuance
- SCYNEXIS's number of shares outstanding increased by 2.93% in one year, reaching 44.66 million shares.
- In the fourth quarter of 2025, the company had 44 million shares outstanding, which was a 3.8% increase from the prior quarter.
Inbound Investments
- SCYNEXIS received a one-time non-refundable payment of $24.8 million from GSK in Q4 2025.
- In 2025, the company recognized a cumulative catch-up of $17.2 million in license agreement revenue associated with a Binding 2025 Memorandum of Understanding with GSK.
Capital Expenditures
- SCYNEXIS reported $0 in capital expenditures in Q4 2021.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| SCYNEXIS Earnings Notes | 12/16/2025 | |
| Is SCYNEXIS Stock Built to Withstand a Pullback? | 10/17/2025 | |
| Day 8 of Gains Streak for SCYNEXIS Stock with 42% Return (vs. -2.5% YTD) [9/11/2025] | 09/12/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 14.63 |
| Mkt Cap | 71.7 |
| Rev LTM | 14,877 |
| Op Inc LTM | 5,948 |
| FCF LTM | 4,739 |
| FCF 3Y Avg | 4,308 |
| CFO LTM | 5,400 |
| CFO 3Y Avg | 4,949 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.9% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Inc Chg LTM | 18.7% |
| Op Inc Chg 3Y Avg | 30.7% |
| Op Mgn LTM | 22.1% |
| Op Mgn 3Y Avg | 18.6% |
| QoQ Delta Op Mgn LTM | -7.5% |
| CFO/Rev LTM | 23.1% |
| CFO/Rev 3Y Avg | 23.4% |
| FCF/Rev LTM | 18.2% |
| FCF/Rev 3Y Avg | 18.0% |
Price Behavior
| Market Price | $4.05 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 05/02/2014 | |
| Distance from 52W High | -57.1% | |
| 50 Days | 200 Days | |
| DMA Price | $6.41 | $6.23 |
| DMA Trend | down | down |
| Distance from DMA | -36.8% | -35.0% |
| 3M | 1YR | |
| Volatility | 75.2% | 72.8% |
| Downside Capture | 350.01 | 110.82 |
| Upside Capture | 14.11 | 35.81 |
| Correlation (SPY) | 39.2% | 18.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.17 | 1.97 | 1.81 | 1.55 | 1.04 | 1.04 |
| Up Beta | 1.18 | 1.69 | 3.58 | 3.24 | 2.76 | 0.99 |
| Down Beta | 1.40 | 0.51 | 0.07 | 0.49 | 0.45 | 1.01 |
| Up Capture | -70% | 20% | 103% | 106% | 24% | 34% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 17 | 28 | 54 | 111 | 323 |
| Down Capture | 711% | 583% | 184% | 127% | 88% | 108% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 12 | 24 | 35 | 70 | 136 | 399 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCYX | |
|---|---|---|---|---|
| SCYX | -32.6% | 72.6% | -0.24 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 8.4% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 19.1% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 12.6% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -5.6% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 14.2% |
| Bitcoin (BTCUSD) | -38.3% | 42.4% | -1.02 | 17.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCYX | |
|---|---|---|---|---|
| SCYX | -42.6% | 85.3% | -0.29 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 19.1% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 24.9% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 7.1% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 6.5% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 20.7% |
| Bitcoin (BTCUSD) | 11.6% | 54.2% | 0.41 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCYX | |
|---|---|---|---|---|
| SCYX | -33.8% | 80.3% | -0.16 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 17.9% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 21.9% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 5.4% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 7.3% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 17.7% |
| Bitcoin (BTCUSD) | 60.4% | 66.8% | 1.00 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/28/2024 | 1.4% | 16.3% | 23.8% |
| 11/9/2022 | -19.6% | -9.8% | -15.6% |
| 8/15/2022 | 2.1% | -4.5% | -2.8% |
| 5/12/2022 | 10.7% | 12.3% | -5.3% |
| 11/10/2021 | 1.2% | 23.4% | 28.0% |
| SUMMARY STATS | |||
| # Positive | 4 | 3 | 2 |
| # Negative | 1 | 2 | 3 |
| Median Positive | 1.7% | 16.3% | 25.9% |
| Median Negative | -19.6% | -7.2% | -5.3% |
| Max Positive | 10.7% | 23.4% | 28.0% |
| Max Negative | -19.6% | -9.8% | -15.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/28/2024 | 1.4% | 16.3% | 23.8% |
| 11/9/2022 | -19.6% | -9.8% | -15.6% |
| 8/15/2022 | 2.1% | -4.5% | -2.8% |
| 5/12/2022 | 10.7% | 12.3% | -5.3% |
| 11/10/2021 | 1.2% | 23.4% | 28.0% |
| SUMMARY STATS | |||
| # Positive | 4 | 3 | 2 |
| # Negative | 1 | 2 | 3 |
| Median Positive | 1.7% | 16.3% | 25.9% |
| Median Negative | -19.6% | -7.2% | -5.3% |
| Max Positive | 10.7% | 23.4% | 28.0% |
| Max Negative | -19.6% | -9.8% | -15.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/29/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/17/2021 | 10-Q |
| 12/31/2020 | 03/29/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/11/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/07/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Angulo, Gonzalez David | Chief Executive Officer | Direct | Buy | 4022026 | 0.00 | 108,695 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Angulo, Gonzalez David | Chief Executive Officer | Direct | Buy | 4022026 | 0.00 | 108,695 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.